Replimune names Howard L. Kaufman, MD, FACS as CMO.
M2 PHARMA-September 11, 2017-Replimune names Howard L. Kaufman, MD, FACS as CMO
(C)2017 M2 COMMUNICATIONS
Oncolytic immunotherapy company Replimune Group Inc revealed on Friday the election of Howard L. Kaufman, MD, FACS as its chief medical officer.
Most recently, Dr Kaufman has served as chief of the Division of Surgical Oncology at the Rutgers Robert Wood Johnson Medical School in Brunswick, NJ as well as president of the Society for the Immunotherapy of Cancer (SITC).
Previously, Dr Kaufman worked at Columbia University in New York City as well as Rush University in Chicago.
Earlier in his career, Dr Kaufman was the chief surgical officer at Rutgers as well as an associate director for Clinical Science of the Rutgers Cancer Institute of New Jersey.
Currently, Dr Kaufman is the editor-in-chief of the Journal of Targeted Therapies in Cancer, a senior associate editor at the Journal of Translational Medicine, president of the Society for Immunotherapy of Cancer (SITC) as well as the recipient of the Daland Prize and the Humanitarian Award from the Melanoma Research Foundation.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 11, 2017|
|Previous Article:||Replimune announces USD55m from its Series B financing with investors.|
|Next Article:||Medivir announces discontinuation by Janssen R&D of JNJ-4178 development.|